BLACKSBURG, Va.--(BUSINESS WIRE)--Intrexon Corporation, a life sciences company focused on the development of transcriptional therapeutics for critical human diseases, announced the appointment of Costas Loullis, Ph.D. as the Vice President of Research and Development (R&D). Dr. Loullis will be responsible for the operational aspects of the Company’s R&D initiatives, including managing a large scientific team and Intrexon’s therapeutic initiatives. Dr. Loullis will report directly to Intrexon’s Chief Executive Officer, Robert Beech, and work collaboratively with Thomas Reed, Ph.D., Chief Science Officer, and J. Mark Braughler, Ph.D., Vice President of Translational Medicine, to advance the Company’s mission.
